Fibrinolysis for patients with intermediate-risk pulmonary embolism.

BACKGROUND The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury as indicated by a positive test for cardiac troponin I or troponin T. The primary outcome was death or hemodynamic decompensation (or collapse) within 7 days after randomization. The main safety outcomes were major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization. RESULTS Of 1006 patients who underwent randomization, 1005 were included in the intention-to-treat analysis. Death or hemodynamic decompensation occurred in 13 of 506 patients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in the placebo group (odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; P=0.02). Between randomization and day 7, a total of 6 patients (1.2%) in the tenecteplase group and 9 (1.8%) in the placebo group died (P=0.42). Extracranial bleeding occurred in 32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo group (P<0.001). Stroke occurred in 12 patients (2.4%) in the tenecteplase group and was hemorrhagic in 10 patients; 1 patient (0.2%) in the placebo group had a stroke, which was hemorrhagic (P=0.003). By day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo group had died (P=0.42). CONCLUSIONS In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).

[1]  Sfedu Ep,et al.  [Acute pulmonary embolism. I]. , 2010, Cardiologia pratica.

[2]  Research Committee on Type 1 Diabetes of the Japan Diabetes Society.  Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism , 1992, The Lancet.

[3]  E. Lesaffre,et al.  Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. , 1992, Journal of the American College of Cardiology.

[4]  Researchcommitteeofthebritish.  Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism*1 , 1992 .

[5]  M. Levine,et al.  Thrombolytic therapy for venous thromboembolism. Complications and contraindications. , 1995, Clinics in chest medicine.

[6]  F. Grodstein,et al.  Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. , 1997, American heart journal.

[7]  J A Parker,et al.  Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. , 1997, Chest.

[8]  Samuel Z Goldhaber,et al.  Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) , 1999, The Lancet.

[9]  S. Konstantinides.  Thrombolysis in submassive pulmonary embolism? Yes , 2003, Journal of thrombosis and haemostasis : JTH.

[10]  J. Eikelboom,et al.  Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials , 2004, Circulation.

[11]  M. Morris.  The Steering Committee , 2004 .

[12]  S. Solomon,et al.  Right Ventricular Enlargement on Chest Computed Tomography: Prognostic Role in Acute Pulmonary Embolism , 2004, Circulation.

[13]  S. Solomon,et al.  Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. , 2005, The American journal of cardiology.

[14]  S. Goldhaber,et al.  Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. , 2005, Archives of internal medicine.

[15]  M. Olschewski,et al.  N-Terminal Pro-Brain Natriuretic Peptide or Troponin Testing Followed by Echocardiography for Risk Stratification of Acute Pulmonary Embolism , 2005, Circulation.

[16]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[17]  G. Agnelli,et al.  Prognostic Value of Troponins in Acute Pulmonary Embolism: A Meta-Analysis , 2007, Circulation.

[18]  S. Laporte,et al.  Thromboembolism : Findings From the Registro Informatizado de la Enfermedad Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous , 2008 .

[19]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[20]  M. Fine,et al.  Weekend Versus Weekday Admission and Mortality After Acute Pulmonary Embolism , 2009, Circulation.

[21]  L. Trinquart,et al.  Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study. , 2010, American journal of respiratory and critical care medicine.

[22]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[23]  J. Kline,et al.  Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association , 2011, Circulation.

[24]  P. Stein,et al.  Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. , 2012, The American journal of medicine.

[25]  S. Goldhaber,et al.  Pulmonary embolism: risk assessment and management. , 2012, European heart journal.

[26]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[27]  M. Sharifi,et al.  Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). , 2013, The American journal of cardiology.

[28]  P. Armstrong,et al.  Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. , 2013, New England Journal of Medicine.

[29]  Ralf-Thorsten Hoffmann,et al.  Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism , 2014, Circulation.